The main purpose of this legislation is to create an office within the Food and Drug Administration (FDA) called the Abraham Accords Office. This office aims to enhance cooperation and regulatory alignment between the United States and countries that have signed the Abraham Accords, which are agreements aimed at normalizing relations between Israel and several Arab nations. Key provisions of the legislation include the establishment of the Abraham Accords Office, which will be led by a director appointed by the Secretary of Health and Human Services.